{"id":211542,"name":"INDIVIOR","slug":"indivior","state":"VA","country":"United States of America","description":"Develops, manufactures, and markets pharmaceutical treatments for opioid use disorders","totalSpending":840000,"filings":17,"yearlySpending":[{"year":2021,"income":120000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":240000}],"issues":[{"code":"HCR","display":"Health Issues"}],"firms":["PUTALASTRATEGIES"],"lobbyists":["CHRISTOPHER PUTALA"],"govEntities":["Justice, Dept of (DOJ)","SENATE","White House Office","Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES"],"sampleDescriptions":["Proposals and issues related to developing, manufacturing, and marketing pharmaceutical treatments for opioid use disorders.","Issues related to developing, manufacturing, and marketing pharmaceutical treatments for opioid use disorders.","Issues related to developing, manufacturing, and marketing pharmaceutical treatments for opioid use disorders.","S.Con.Res.14-Budget Resolution (issues related to pharmaceutical treatments for opioid use disorders). HR 955/S.285-Medicare Reentry Act of 2021.","S.Con.Res.14-Budget Resolution (issues related to pharmaceutical treatments for opioid use disorders). HR 955/S.285-Medicare Reentry Act of 2021."]}